Sorry, this job is no longer available.

Method Development Specialist


For nearly 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

 

We are seeking an experienced Method Development Specialist for our Safety Assessement site located in Tranent, East Lothian.

 

Due to our continued growth and success, we can offer rewarding opportunities in a research environment.  Working as a Method Development Specialist, you’ll join a team whose primary focus is to design and develop assays in order to support regulated sample analyses. These samples arise from both preclinical and clinical studies aimed at providing data for the development and registration of pharmaceuticals.

 

Duties and responsibilities include:

  • Conducting and overseeing LC-MS/MS method development projects
  • Communicating with Clients at a high level on bioanalytical science and strategy
  • The post holder may also be expected to provide bioanalytical leadership and have significant experience in developing junior staff

 

Applicants should have:

  • MSc or equivalent experience in Chemistry related discipline.
  • A strong track record of successful method development for LC-MS/MS endpoints preferably within a contract research setting.
  • A good understanding of appropriate regulatory guidance in bioanalytical method validation in addition to current GLP/GCP regulations
  • Good communication skills in order to ensure successful outcomes for the company and its partners

 

The closing date for this position is Monday, 06 August 2018.

 

 

About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.

About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.

For more information, please visit www.criver.com.